Savolitinib

Generic Name: Savolitinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₅N_₉

CAS Number: 1313725-88-0

Unique Ingredient Identifier: 2A2DA6857R

Background: Savolitinib has been used in trials studying the treatment and health services research of Tumor, Food Effect, Gastric Cancer, Health Subjects, and Colorectal Cancer, among others.

Indication: 用于含铂化疗后疾病进展或不耐受标准含铂化疗的、具有间质-上皮转化因子（MET）外显子14跳变的局部晚期或转移性非小细胞肺癌成人患者。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

Phase 3

Active, not recruiting

Conditions: Papillary Renal Cell Carcinoma

Interventions: Drug: savolitinib
Drug: sunitinib
Drug: durvalumab

First Posted Date: 2021-09-13

Last Posted Date: 2024-12-16

Lead Sponsor: AstraZeneca

Target Recruit Count: 147

Registration Number: NCT05043090

Locations: 🇬🇧
Research Site, London, United Kingdom

Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

Phase 3

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Placebo
Drug: Savolitinib

First Posted Date: 2021-08-18

Last Posted Date: 2023-03-30

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 320

Registration Number: NCT05009836

Locations: 🇨🇳
Guangdong General Hospital, Guangzhou, China

Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients

Phase 2

Recruiting

Conditions: Gastric Cancer
Esophagogastric Junction Disorder

Interventions: Drug: Savolitinib

First Posted Date: 2021-06-11

Last Posted Date: 2023-03-30

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 75

Registration Number: NCT04923932

Locations: 🇨🇳
Beijing Cancer Hopspital, Beijing, Beijing, China

Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients

Phase 3

Recruiting

Conditions: Non-small Cell Lung Cancer Metastatic

Interventions: Drug: Savolitinib

First Posted Date: 2021-06-11

Last Posted Date: 2021-09-02

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 163

Registration Number: NCT04923945

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Body

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Savolitinib
Drug: Midazolam

First Posted Date: 2019-12-05

Last Posted Date: 2021-08-19

Lead Sponsor: AstraZeneca

Target Recruit Count: 14

Registration Number: NCT04187456

Locations: 🇺🇸
Research Site, Baltimore, Maryland, United States

A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine

Phase 1

Completed

Conditions: Solid Tumours

Interventions: Drug: Savolitinib
Drug: Famotidine

First Posted Date: 2019-11-26

Last Posted Date: 2020-07-07

Lead Sponsor: AstraZeneca

Target Recruit Count: 16

Registration Number: NCT04179071

Locations: 🇺🇸
Research Site, Baltimore, Maryland, United States

A Study to Evaluate the Amount of Drug That Becomes Available in the Blood Circulation When Savolitinib is Administered Alone and in Combination With Itraconazole

Phase 1

Completed

Conditions: Solid Tumour

Interventions: Drug: Savolitinib
Drug: Itraconazole

First Posted Date: 2019-10-10

Last Posted Date: 2020-01-23

Lead Sponsor: AstraZeneca

Target Recruit Count: 16

Registration Number: NCT04121910

Locations: 🇺🇸
Research Site, Glendale, California, United States

A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Savolitinib
Drug: Rifampicin

First Posted Date: 2019-10-08

Last Posted Date: 2020-04-03

Lead Sponsor: AstraZeneca

Target Recruit Count: 40

Registration Number: NCT04118842

Locations: 🇺🇸
Research Site, Baltimore, Maryland, United States

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Phase 2

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Durvalumab
Drug: Osimertinib
Drug: Necitumumab
Drug: Carboplatin
Drug: Alectinib
Drug: Selumetinib
Drug: Datopotamab deruxtecan
Drug: Savolitinib
Drug: Gefitinib
Drug: Selpercatinib
Drug: Pemetrexed
Drug: Etoposide
Drug: Cisplatin

First Posted Date: 2019-05-10

Last Posted Date: 2024-07-17

Lead Sponsor: AstraZeneca

Target Recruit Count: 248

Registration Number: NCT03944772

Locations: 🇸🇪
Research Site, Stockholm, Sweden

Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance

Phase 2

Active, not recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Durvalumab (MEDI4736)
Drug: DOCETAXEL
Drug: Monalizumab (IPH2201)
Drug: Oleclumab (MEDI9447)
Drug: Ceralasertib (AZD6738)
Drug: Savolitinib

First Posted Date: 2019-02-07

Last Posted Date: 2024-05-03

Lead Sponsor: Assistance Publique Hopitaux De Marseille

Target Recruit Count: 114

Registration Number: NCT03833440

Locations: 🇫🇷
Assistance Publique Hopitaux de Marseille, Marseille, France

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy